
ITM Presents Positive Topline Phase 3 COMPETE Trial Data with n.c.a. 177Lu-edotreotide (ITM-11), a Targeted ...
Trial met primary endpoint, demonstrating clinically and statistically significant improvement in progression-free survival (PFS) compared to everolimus Median PFS was 23.9 months on n.c.a. 177Lu-edotreotide v. 14.1 months on everolimus; p value=0.022 …